FierceBiotechOriginal article
{"a":[{"_":"Lilly drops another gene therapy trial from $1B Prevail buyout ","$":{"href":"/biotech/eli-lilly-drops-another-gene-therapy-trial-1b-prevail-buyout","hreflang":"en"}}]}
negativeNegative
AI Analysis
Summary
Eli Lilly has discontinued another gene therapy trial from its $1 billion acquisition of Prevail Therapeutics, reducing the likelihood of a positive return on the investment.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Trial discontinued
Importance:6/10
Sentiment:
-0.70
gene therapytrial discontinuationacquisitionPrevail TherapeuticsR&D setback
Read the original article
Published by FierceBiotech on August 5, 2026 8:37 AM